Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib in NF1-related symptomatic plexiform neurofibromas
2024-516593-30-00Phase 2Authorised
- Sponsor
- Erasmus MC
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trametinib in neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN), sponsored by Erasmus MC. Primary endpoint: Tumor volume on volumetric MRI analysis. Planned start Sep 2024; status: authorised.
02
Drugs
trametinib
03
Conditions
neurofibromatosis type 1 (NF1)plexiform neurofibroma (PN)
Beyond the preview
Go deeper on 2024-516593-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516593-30-00.